Logo image of BCOV

BRIGHTCOVE (BCOV) Stock Fundamental Analysis

NASDAQ:BCOV - US10921T1016 - Common Stock

4.45 USD
+0.01 (+0.23%)
Last: 2/3/2025, 8:15:51 PM
4.45 USD
0 (0%)
After Hours: 2/3/2025, 8:15:51 PM
Fundamental Rating

3

BCOV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 83 industry peers in the IT Services industry. While BCOV seems to be doing ok healthwise, there are quite some concerns on its profitability. BCOV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year BCOV was profitable.
BCOV had a positive operating cash flow in the past year.
In the past 5 years BCOV reported 4 times negative net income.
Each year in the past 5 years BCOV had a positive operating cash flow.
BCOV Yearly Net Income VS EBIT VS OCF VS FCFBCOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

1.2 Ratios

BCOV has a Return On Assets of -4.34%. This is comparable to the rest of the industry: BCOV outperforms 40.51% of its industry peers.
BCOV has a Return On Equity of -9.58%. This is comparable to the rest of the industry: BCOV outperforms 41.77% of its industry peers.
Industry RankSector Rank
ROA -4.34%
ROE -9.58%
ROIC N/A
ROA(3y)-4.02%
ROA(5y)-5.56%
ROE(3y)-9.19%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
BCOV Yearly ROA, ROE, ROICBCOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20

1.3 Margins

BCOV has a better Gross Margin (61.60%) than 81.01% of its industry peers.
BCOV's Gross Margin has been stable in the last couple of years.
BCOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.06%
GM growth 5Y0.65%
BCOV Yearly Profit, Operating, Gross MarginsBCOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

4

2. Health

2.1 Basic Checks

BCOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
BCOV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BCOV has been increased compared to 5 years ago.
BCOV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCOV Yearly Shares OutstandingBCOV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
BCOV Yearly Total Debt VS Total AssetsBCOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

BCOV has an Altman-Z score of 0.08. This is a bad value and indicates that BCOV is not financially healthy and even has some risk of bankruptcy.
BCOV has a worse Altman-Z score (0.08) than 83.54% of its industry peers.
There is no outstanding debt for BCOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.08
ROIC/WACCN/A
WACC10.73%
BCOV Yearly LT Debt VS Equity VS FCFBCOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.75 indicates that BCOV may have some problems paying its short term obligations.
BCOV has a worse Current ratio (0.75) than 88.61% of its industry peers.
BCOV has a Quick Ratio of 0.75. This is a bad value and indicates that BCOV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.75, BCOV is not doing good in the industry: 88.61% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.75
BCOV Yearly Current Assets VS Current LiabilitesBCOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

4

3. Growth

3.1 Past

BCOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 145.45%, which is quite impressive.
The Revenue has decreased by -0.22% in the past year.
Measured over the past years, BCOV shows a small growth in Revenue. The Revenue has been growing by 4.07% on average per year.
EPS 1Y (TTM)145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y0.64%
Revenue growth 5Y4.07%
Sales Q2Q%-2.02%

3.2 Future

The Earnings Per Share is expected to grow by 64.74% on average over the next years. This is a very strong growth
Based on estimates for the next years, BCOV will show a small growth in Revenue. The Revenue will grow by 0.01% on average per year.
EPS Next Y100%
EPS Next 2Y64.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.51%
Revenue Next 2Y0.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BCOV Yearly Revenue VS EstimatesBCOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BCOV Yearly EPS VS EstimatesBCOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2025 0 0.2 -0.2 0.4

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 89.00, which means the current valuation is very expensive for BCOV.
The rest of the industry has a similar Price/Earnings ratio as BCOV.
When comparing the Price/Earnings ratio of BCOV to the average of the S&P500 Index (27.08), we can say BCOV is valued expensively.
With a Price/Forward Earnings ratio of 124.65, BCOV can be considered very expensive at the moment.
BCOV's Price/Forward Earnings ratio is in line with the industry average.
BCOV's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.72.
Industry RankSector Rank
PE 89
Fwd PE 124.65
BCOV Price Earnings VS Forward Price EarningsBCOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

BCOV's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BCOV is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 51.96
EV/EBITDA 23.8
BCOV Per share dataBCOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

BCOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BCOV's earnings are expected to grow with 64.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y64.74%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for BCOV!.
Industry RankSector Rank
Dividend Yield N/A

BRIGHTCOVE

NASDAQ:BCOV (2/3/2025, 8:15:51 PM)

After market: 4.45 0 (0%)

4.45

+0.01 (+0.23%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners70.58%
Inst Owner Change-99.81%
Ins Owners5.23%
Ins Owner Change0%
Market Cap201.05M
Analysts45.71
Price Target4.54 (2.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)56.43%
Max EPS beat(2)143.57%
EPS beat(4)4
Avg EPS beat(4)114.38%
Min EPS beat(4)56.43%
Max EPS beat(4)161.44%
EPS beat(8)6
Avg EPS beat(8)77.66%
EPS beat(12)10
Avg EPS beat(12)100.79%
EPS beat(16)14
Avg EPS beat(16)114.38%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.56%
Max Revenue beat(2)0.87%
Revenue beat(4)2
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.87%
Revenue beat(8)2
Avg Revenue beat(8)-1%
Revenue beat(12)6
Avg Revenue beat(12)-0.14%
Revenue beat(16)10
Avg Revenue beat(16)0.35%
PT rev (1m)0%
PT rev (3m)14.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)N/A
EPS NY rev (3m)100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.25%
Valuation
Industry RankSector Rank
PE 89
Fwd PE 124.65
P/S 1.01
P/FCF 51.96
P/OCF 14.73
P/B 2.11
P/tB 11.84
EV/EBITDA 23.8
EPS(TTM)0.05
EY1.12%
EPS(NY)0.04
Fwd EY0.8%
FCF(TTM)0.09
FCFY1.92%
OCF(TTM)0.3
OCFY6.79%
SpS4.42
BVpS2.11
TBVpS0.38
PEG (NY)0.89
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.34%
ROE -9.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.6%
FCFM 1.94%
ROA(3y)-4.02%
ROA(5y)-5.56%
ROE(3y)-9.19%
ROE(5y)-12.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.06%
GM growth 5Y0.65%
F-Score7
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 50.16%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion 186.6%
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.75
Altman-Z 0.08
F-Score7
WACC10.73%
ROIC/WACCN/A
Cap/Depr(3y)143.44%
Cap/Depr(5y)123.4%
Cap/Sales(3y)7.87%
Cap/Sales(5y)6.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y100%
EPS Next 2Y64.74%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.22%
Revenue growth 3Y0.64%
Revenue growth 5Y4.07%
Sales Q2Q%-2.02%
Revenue Next Year-1.51%
Revenue Next 2Y0.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year979.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.43%
OCF growth 3Y-40.43%
OCF growth 5Y12.05%